Clinical Epigenetics goes open access with BioMed Central

Liz Bal

Clinical Epigenetics, the official journal of the
Clinical Epigenetics Society, has published its first open access articles
today.

Led
by Professor Ulrich Mahlknecht, the journal
publishes articles covering all
aspects of epigenetic principles and mechanisms, along with reports on defects
of epigenetic regulation, in relation to human disease, diagnosis and therapy.

“Clinical Epigenetics is the first journal dedicated to the connection of
epigenetic patterns to human physiology and disease. The transition of Clinical Epigenetics to an open access publishing model has been made
with the intention to reach out to the continuously increasing audience
that expresses an interest in the field”, says Editor-in-Chief
Ulrich Mahlknecht, in his inaugural Editorial.

The first open access articles published today include
a review from
Rajendran et al. summarizing how
dietary phytochemicals that affect the epigenome can also trigger DNA damage
and repair mechanisms, research from Soubry et al. reporting a race-specific
response to the use of anti-depressants during pregnancy, and insights from Hsu
et al. into how suforaphane may
regulate gene expression as a prostate cancer chemopreventive agent.

Clinical Epigenetics, previously
published by Springer, is an exciting
addition to BioMed Central’s open access portfolio. To access articles
published prior to this transition, please see SpringerLink, and to receive regular updates of the
current content, sign up for article alerts.

Liz Bal

Liz Bal

Associate Publisher at BioMed Central
Liz completed an MSci in Biology at Imperial College London, before joining BioMed Central in 2010. Now, as an Associate Publisher in the Biological Sciences team, she is responsible for the development of a portfolio of neuroscience, biotechnology and cell biology journals.
Liz Bal

Latest posts by Liz Bal (see all)

View the latest posts on the On Biology homepage

Comments